TELA Bio downgraded by Piper Sandler with a new price target
$TELA
Medical/Dental Instruments
Health Care
Piper Sandler downgraded TELA Bio from Overweight to Neutral and set a new price target of $2.00 from $5.00 previously
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/21/2025 | $5.00 → $2.00 | Overweight → Neutral | Piper Sandler |
| 5/31/2022 | $17.00 | Buy | Lake Street |
Piper Sandler downgraded TELA Bio from Overweight to Neutral and set a new price target of $2.00 from $5.00 previously
Lake Street initiated coverage of TELA Bio with a rating of Buy and set a new price target of $17.00
MALVERN, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the second quarter ended June 30, 2025. Recent Highlights Delivered revenue of $20.2 million in the second quarter 2025, representing growth of 26% over the prior year period and sequential growth of 9% over the first quarter of 2025;Increased demand for OviTex® and OviTex PRS Reinforced Tissue Matrix products during the second quarter, resulting in year-over-year revenue increase for each product of approximately 12% and 53%, respectively;Appointed Jeffrey Bliz
MALVERN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 10,200 shares of its common stock to fourteen newly-hired employees, with a grant date of August 5, 2025 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or
MALVERN, Pa., July 23, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in the Canaccord Genuity 45th Annual Growth Conference. TELA's management is scheduled to present at the Canaccord Genuity 45th Annual Growth Conference at 10:00 am ET on August 13th, 2025. Interested parties can access the live and archived webcast at ir.telabio.com. About TELA Bio, Inc.TELA Bio, Inc. (NASDAQ:TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prior
MALVERN, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of Jeffrey Blizard as President of TELA Bio, effective immediately. Mr. Blizard, who has served on TELA Bio's Board of Directors for the past year, brings deep industry experience and proven leadership to this expanded role. "This is an important inflection point for TELA Bio," said Antony Koblish, Co-Founder and Chief Executive Officer of TELA Bio. "As we move into the next phase of our growth trajectory, we believe the addition of Jeff—a highly respected l
MALVERN, Pa., June 04, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that it has appointed Jeffrey Blizard, the Global Head of Surgical Sales for Abiomed, a medical device technology company that operates as a stand-alone business within Johnson & Johnson's MedTech Segment, to its Board of Directors, effective June 4, 2024. "We are excited to have Jeff join our Board as we continue to develop and optimize our sales force," said Antony Koblish, co-founder, President and Chief Executive Officer of TELA Bio. "Jeff's exceptional sales leader
MALVERN, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of Greg Firestone as the Company's new Chief Commercial Officer. In this role, Mr. Firestone will oversee the Company's commercial operations, including key product launches, sales team training, market development, as well as strategic initiatives to optimize market access and reimbursement strategy across the Company's product lines. "Greg has been an instrumental player in the TELA Bio story, supporting our commercial strategy and cultivating each of our key group
MALVERN, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the second quarter ended June 30, 2025. Recent Highlights Delivered revenue of $20.2 million in the second quarter 2025, representing growth of 26% over the prior year period and sequential growth of 9% over the first quarter of 2025;Increased demand for OviTex® and OviTex PRS Reinforced Tissue Matrix products during the second quarter, resulting in year-over-year revenue increase for each product of approximately 12% and 53%, respectively;Appointed Jeffrey Bliz
MALVERN, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report second quarter 2025 financial results on Monday, August 11, 2025. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Second Quarter Earnings Conference Call and Webcast DetailsInvestors interested in listening to the conference call should register online. Participants are required to register a day in advance or at minimum 15 minutes before
MALVERN, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights Delivered revenue of $18.5 million in the first quarter 2025, representing growth of 12% over the prior year period and sequential growth of 5% over the fourth quarter of 2024;Increased demand for OviTex® and OviTex PRS Reinforced Tissue Matrix products during the first quarter, resulting in year-over-year revenue increase for each product of approximately 15% and 2%, respectively;Commenced full U.S. comme
SCHEDULE 13G/A - TELA Bio, Inc. (0001561921) (Subject)
S-8 - TELA Bio, Inc. (0001561921) (Filer)
10-Q - TELA Bio, Inc. (0001561921) (Filer)
4 - TELA Bio, Inc. (0001561921) (Issuer)
4 - TELA Bio, Inc. (0001561921) (Issuer)
4 - TELA Bio, Inc. (0001561921) (Issuer)
4 - TELA Bio, Inc. (0001561921) (Issuer)
4 - TELA Bio, Inc. (0001561921) (Issuer)
4 - TELA Bio, Inc. (0001561921) (Issuer)
SC 13G/A - TELA Bio, Inc. (0001561921) (Subject)
SC 13G - TELA Bio, Inc. (0001561921) (Subject)
SC 13G/A - TELA Bio, Inc. (0001561921) (Subject)